Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : offers its newest HIV drug candidate to patent pool for low-cost production

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:13pm CET

Gilead Sciences is licensing its newest HIV drug candidate, bictegravir, to the U.N.-backed Medicines Patent Pool, meaning it will be produced and sold at a lower cost in 116 low- and middle-income countries once it is approved.

Gilead said it will include the HIV-1 candidate in its existing agreements with generic drugmakers Sun Pharmaceutical Industries, Strides Shasun, Mylan and SeQuent Scientific, as a single agent or in fixed-dose combinations with other HIV medicines, upon regulatory approval in the U.S. It also will allow the MPP to sub-license it to other generic producers in India, China and South Africa.

Competition among manufacturers has reduced the lowest price of a Gilead HIV generic therapy by 80 percent since 2006, to as low as $3.50 per patient per month. Ninety-nine percent of people taking Gileads HIV therapies in developing countries receive generic medicine, Gilead said in an announcement today.

Of course, it is the branded version in the U.S. and Europe, where drug approvals are currently pending, that Gilead is most interested in and where it will compete with GlaxoSmithKlines $1.2 billion seller Tivicay (dolutegravir). The FDA has set a Feb.12, 2018 target date for consideration.

Analysts initially believed bictegravir, if approved, was going to be a red-hot competitor to the GSK med but phase 3 data released last spring cooled those expectations somewhat. While four studies of the investigational integrase strand transfer inhibitor hit their primary endpoints by measuring up to Tivicay and other antiretroviral agents, they didnt prove that bictegravir is superior. Then in data released today, it reported the same finding at 48 weeks.

GSK, which has been aggressively building its HIV focused ViiV Healthcare, is taking another tack in its assault on market leader Gileads $10 billion-plus HIV franchise. The U.K.-based company is betting on a two-drug, dolutegravir-containing regimen that could potentially cut down on the side-effect burden of Gileads three-drug approaches, and their cost, too.

(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
02/15GILEAD SCIENCES : New Data from Gilead Sciences Illuminate Findings in Antiretro..
AQ
02/15GILEAD SCIENCES : U.S. Food and Drug Administration Approves Gilead's Biktarvy® ..
AQ
02/15GILEAD SCIENCES : to Present at the RBC Capital Markets 2018 Global Healthcare C..
AQ
02/15GILEAD SCIENCES : Today’s Research Reports on Trending Tickers: Gilead Sciences ..
AC
02/12GILEAD SCIENCES : to Present at the RBC Capital Markets 2018 Global Healthcare C..
AQ
02/12PFIZER : ViiV Healthcare files patent infringement litigation against Gilead Sci..
AQ
02/10Gilead`s Biktarvy wins megablockbuster HIV nod, and rival GlaxoSmithKline str..
AQ
02/09GILEAD SCIENCES : U.S. Food and Drug Administration Approves Gileads Biktarvy
AQ
02/09GILEAD SCIENCES : Glaxo sues US firm for allegedly infringing on HIV drug patent
AQ
02/08GILEAD SCIENCES : to Present at the RBC Capital Markets 2018 Global Healthcare C..
BU
More news
News from SeekingAlpha
02/19Healthcare In Transition 
02/19VALUATION DASHBOARD : Healthcare - Update 
02/18Should We Make 'Charitable Investments?' Is There Such A Thing? 
02/18Gilead wins big reversal of patent verdict 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
Financials ($)
Sales 2018 21 265 M
EBIT 2018 11 289 M
Net income 2018 6 975 M
Debt 2018 16 887 M
Yield 2018 2,79%
P/E ratio 2018 15,36
P/E ratio 2019 14,46
EV / Sales 2018 5,75x
EV / Sales 2019 5,66x
Capitalization 105 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 88,7 $
Spread / Average Target 9,9%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055
JUNO THERAPEUTICS INC87.75%9 798